COMMUNIQUÉS West-GlobeNewswire

Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025
29/10/2025
- First-in-human data validating direct targeting of NETs as a novel therapeutic approach in autoimmunity and inflammatory diseases - DNASE1L3 analogue therapy degrades NETs and results in rapid, multi-organ clinical [...]
Vireo Growth Inc. and Verano Holdings Corp. Announce Resolution of Litigation Matters
29/10/2025
CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) [...]
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
29/10/2025
BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business [...]
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
29/10/2025
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
29/10/2025
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved’ with oral blarcamesine compared to ADNI Restoring impaired [...]
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
29/10/2025
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Hyperion DeFi Announces Strategic Partnership with Felix to Launch HIP-3 Powered Perpetual Futures Market
29/10/2025
New Hyperliquid Product Compounds Yield on 500,000 HYPE Staked by the Company LAGUNA HILLS, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S [...]
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
29/10/2025
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- [...]
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
29/10/2025
BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class [...]
Immutep Quarterly Activities Report Q1 FY26
29/10/2025
Media Release Pivotal TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build momentum and is recruiting patients at a growing number of [...]
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
29/10/2025
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1. [...]
DEBRA Research Invests in Eliksa Therapeutics to Advance ELK-003, a Biological Eye Drop for Epidermolysis Bullosa-Related Ocular Complications
29/10/2025
The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with DEBRA Chile has [...]
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
29/10/2025
– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass., Oct [...]
Turning Point of Tampa Expands Access to Mental Health Care with Launch of Virtual Intensive Outpatient Program
29/10/2025
Leading behavioral healthcare provider brings evidence-based treatment directly to patients’ homes through innovative virtual IOP Tampa, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a trusted behavioral [...]
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
29/10/2025
CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
29/10/2025
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, [...]
REPEAT – MEDIA ADVISORY: Patients join Day of Action at Ontario Legislature to demand action on complaints about private clinics’ charges
29/10/2025
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- On Wednesday October 29, patients who have been wrongfully charged for surgeries and diagnostic tests at private clinics will be joined by people from across Ontario at the [...]
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
29/10/2025
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal [...]
Sofwave to Participate in Upcoming November Investor Conferences
29/10/2025
SAN CLEMENTE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that management will [...]

Pages